Tongjitang Chinese Medicines Company (同济堂药业) released another in a year-long series of disappointing earnings reports. In its Q3, Tongjitang’s revenues dropped 13% to 110 million RMB ($16.3 million), and net income fell 86% to 7 million RMB ($1.1 million), which is equivalent to earnings per ADS of 3 cents. The company also lowered its official revenue guidance for 2008 to 450 million RMB, down from 596 million RMB last year. There was a small measure of good news in the earnings announcement. More details...
Stock Symbol: (NYSE: TCM)
Sorry... this feature or article is only available to subscribers.